Last reviewed · How we verify
SIM0916 — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
SIM0916 (SIM0916) — Simcere Pharmaceutical Co., Ltd. SIM0916 is a small molecule inhibitor that targets a specific molecular pathway involved in disease pathogenesis, though the exact mechanism requires further clarification.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SIM0916 TARGET | SIM0916 | Simcere Pharmaceutical Co., Ltd | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). SIM0916 — Competitive Intelligence Brief. https://druglandscape.com/ci/sim0916. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab